Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Common Equity (2016 - 2026)

Ani Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at $540.7 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 33.95% to $540.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $540.7 million, a 33.95% increase, with the full-year FY2025 number at $540.7 million, up 33.95% from a year prior.
  • Common Equity hit $540.7 million in Q4 2025 for Ani Pharmaceuticals, up from $505.8 million in the prior quarter.
  • Over the last five years, Common Equity for ANIP hit a ceiling of $540.7 million in Q4 2025 and a floor of -$92.6 million in Q3 2022.
  • Historically, Common Equity has averaged $190.5 million across 5 years, with a median of $101.8 million in 2021.
  • Biggest five-year swings in Common Equity: tumbled 864400.0% in 2023 and later soared 25290750.0% in 2025.
  • Tracing ANIP's Common Equity over 5 years: stood at -$3.1 million in 2021, then skyrocketed by 498.3% to $12.2 million in 2022, then tumbled by 182.85% to -$10.1 million in 2023, then surged by 4104.36% to $403.7 million in 2024, then soared by 33.95% to $540.7 million in 2025.
  • Business Quant data shows Common Equity for ANIP at $540.7 million in Q4 2025, $505.8 million in Q3 2025, and -$31.6 million in Q2 2025.